Related Experiment Video

Updated: Feb 24, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials

Jen-Wei Liu1,2, Chiehfeng Chen3,4,5, El-Wui Loh6

  • 1a Department of Pharmacy , Shin Kong Wu Ho-Su Memorial Hospital , Taipei , Taiwan.

Current Medical Research and Opinion
|August 17, 2017
PubMed
Abstract

Insights

Tyrosine kinase inhibitors (TKIs) improve progression-free survival and response rates in advanced thyroid cancer. Careful patient evaluation is recommended to balance TKI benefits and toxicity.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Radioiodine-refractory advanced or metastatic thyroid cancer presents a significant clinical challenge with poor prognosis.
  • Tyrosine kinase inhibitors (TKIs) have emerged as a potential therapeutic option for these patients.

Purpose of the Study:

  • To evaluate the effectiveness and safety of TKIs in treating advanced or metastatic thyroid cancer through a meta-analysis of randomized controlled trials.
  • To assess the impact of TKIs on overall survival, progression-free survival, objective response rate, and adverse events.

Main Methods:

  • A meta-analysis was conducted on randomized controlled trials published up to April 2017.
  • Random effects models were used to calculate pooled effect sizes for overall survival, progression-free survival, objective response rate, and adverse events.

Main Results:

  • Six studies involving 1615 patients were analyzed.
  • TKI treatment significantly improved progression-free survival in differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC).
  • Overall survival was significantly prolonged in DTC patients treated with TKIs, and the objective response rate was significantly improved, though adverse events were more frequent.

Conclusions:

  • TKIs demonstrate significant efficacy in improving progression-free survival and response rates for advanced or metastatic DTC and MTC.
  • Thorough patient health status evaluation and cautious TKI use are crucial for maximizing therapeutic benefits while minimizing toxicity.
Keywords:
Tyrosine kinase inhibitorsmeta-analysisradioiodine refractorytargeted therapythyroid cancer

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
45
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
19.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
593
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.5K